Cytokines in pancreatic carcinoma
- 3 November 2004
- Vol. 101 (12), 2727-2736
- https://doi.org/10.1002/cncr.20672
Abstract
BACKGROUND: Cytokines have been implicated in diverse processes that are relevant to pancreatic carcinoma, including cachexia, asthenia, and tumor growth. The objective of this study was to examine the association between serum levels of proinflammatory and antiinflammatory or angiogenic cytokines and the outcomes of patients with pancreatic carcinoma.METHODS: Serum cytokine levels were measured by enzyme‐linked immunosorbent assay from 51 patients with pancreatic carcinoma and from 48–62 healthy volunteers. Cytokine levels were compared with disease manifestations and overall survival.RESULTS: Circulating levels of vascular endothelial growth factor, tumor necrosis factor alpha, interleukin‐1α (IL‐1α), and IL‐1β were not elevated significantly in patients with pancreatic carcinoma, but levels of IL‐6, IL‐8, IL‐10, and IL‐1 receptor antagonist (IL‐1RA) were elevated significantly (P < 0.05). Cytokine levels were dichotomized based on an analysis of null Martingale residuals. Patients who had IL‐6 levels > 5.2 pg/mL or IL‐10 levels > 9.8 pg/mL had significantly worse survival compared with patients who had lower IL‐6 or IL‐10 levels (P < 0.05). IL‐8 levels were not associated with survival differences. Patients who had IL‐1RA levels < 159 pg/mL had significantly worse survival compared with patients who had higher IL‐1RA levels (P < 0.05). Higher IL‐6, IL‐10, and IL‐8 levels were associated with poor performance status and/or weight loss. In multivariate analysis, only T4 tumors and high IL‐6 levels were selected as independent prognostic factors for poor survival.CONCLUSIONS: Circulating levels of several cytokines were high in patients with pancreatic carcinoma, and their association with weight loss and poor performance status suggested that they may be involved in these disease manifestations. Furthermore, serum cytokine levels, in particular IL‐6, may be a useful prognostic marker. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 49 references indexed in Scilit:
- Circulating Levels of Interleukin-10 and Interleukin-6 in Gastric and Colon Cancer Patients Before and After Surgery: Relationship with Radicality and OutcomeJournal of Interferon & Cytokine Research, 2002
- Long-Term Consequences of Interleukin-6 Overexpression in Transgenic MiceDNA and Cell Biology, 1992
- Increased levels of circulating interleukin‐6 in patients with hodgkin's diseaseHematological Oncology, 1991
- Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parametersAnnals of Hematology, 1991
- Interleukin 10: a novel stimulatory factor for mast cells and their progenitors.The Journal of Experimental Medicine, 1991
- Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells.The Journal of Experimental Medicine, 1990
- Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10International Immunology, 1990
- Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity.The Journal of Experimental Medicine, 1990
- Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.The Journal of Experimental Medicine, 1989
- Interleukin 6 gene expression in normal and neoplastic B cells.Journal of Clinical Investigation, 1989